VANCOUVER and SAN DIEGO, Sept. 10 /PRNewswire-FirstCall/ - MIGENIX Inc. (TSX: MGI; OTC: MGIFF), a clinical-stage developer of drugs for infectious diseases will present results of viral resistance studies with its anti-HCV agent celgosivir at the 14th International Symposium on Hepatitis C Virus and Related Viruses (http://www.hcv2007.com) being held September 9th to 13th 2007 in Glasgow, Scotland.
The presentation entitled: "Celgosivir (MX-3253) Resistance Profile Using Bovine Viral Diarrhea Virus" will be made today from 5:30pm to 8:00pm, Glasgow time (9:30am - noon Pacific Time) by Dominique Dugourd, Ph.D., Microbiology Group Leader at MIGENIX. A copy of the presentation and the related Abstract (abstract P-223) will be available at http://www.migenix.com at the start of the presentation. The conference covers a broad spectrum of topics from molecular virology to new antiviral therapies and attracts major scientists and thought leaders in the field.
Jacob Clement, Ph.D., CSO at MIGENIX and coauthor of the paper, believes that the results of these laboratory studies with the accepted HCV surrogate virus BVDV, indicate that the emergence of resistance in a clinical setting is unlikely to occur. "We were unable to induce viral resistance to celgosivir even after repeated exposure to high levels of the agent in a system which rapidly develops relatively high levels of resistance to other direct acting antivirals."
About Celgosivir (MX-3253)
Celgosivir is an oral alpha-glucosidase I inhibitor and is currently
the only anti-HCV drug in clinical development that acts on host-directed
glycosylation. In preclinical studies, celgosivir has shown excellent in
vitro synergy with various interferons in the clinic or in development
including Pegasys, PEG-Intron, Infergen, Alferon and IFN-omega (with or
without ribavirin) and other drugs in develo
|SOURCE MIGENIX Inc.|
Copyright©2007 PR Newswire.
All rights reserved